Scinai Immunotherapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SCNI Nasdaq 8731 https://www.scinai.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scinai Immunotherapeutics Ltd

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies - Sep 16th, 2024 11:00 am
Scinai Regains Full Compliance with Nasdaq Listing Requirements - Aug 29th, 2024 10:30 am
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000 - Aug 21st, 2024 12:45 pm
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder - Aug 20th, 2024 1:30 pm
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23 - Aug 15th, 2024 11:00 am
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity - Aug 13th, 2024 11:00 am
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb - Jul 23rd, 2024 11:00 am
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model - Jul 15th, 2024 11:00 am
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity - Jul 8th, 2024 12:14 pm
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Jul 3rd, 2024 1:32 pm
Scinai Publishes Q1 2024 Financial Results and Provides Business Update - Jul 2nd, 2024 12:12 pm
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity. - Jun 13th, 2024 11:00 am
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement - Jun 7th, 2024 11:00 am
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance - May 24th, 2024 8:01 pm
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update - May 15th, 2024 8:01 pm
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal - May 6th, 2024 1:21 pm
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG - Apr 10th, 2024 11:00 am
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services - Apr 8th, 2024 11:00 am
Scinai leadership to attend BIO-Europe Spring 2024 - Mar 12th, 2024 12:00 pm
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024 - Feb 29th, 2024 1:45 pm